Editorial Policy

Every article published on PeptideGuider.com begins with primary source research. Before any editorial content is drafted, the relevant regulatory status, clinical evidence base, and published literature are reviewed directly – not through secondary summaries, vendor-produced materials, or social media discussion.

Our standard research process includes:

• Checking the current regulatory status of the compound against FDA databases, MHRA registers, and TGA records
• Reviewing published literature via PubMed, Google Scholar, and institutional repositories
• Searching clinical trial registries (ClinicalTrials.gov, EU Clinical Trials Register, ANZCTR) for ongoing, completed, and terminated studies
• Reviewing regulatory enforcement actions, warning letters, and import alerts where relevant
• Cross-referencing claims against multiple independent sources before publication

Not all sources carry equal weight. PeptideGuider.com operates a clear source hierarchy when evaluating claims and evidence:

• Tier 1 – Primary regulatory sources: FDA filings, MHRA registers, TGA databases, enforcement actions, official guidance documents
• Tier 2 – Peer-reviewed research: Published clinical trials, systematic reviews, meta-analyses in indexed journals
• Tier 3 – Clinical practice data: Case reports, observational studies, pharmacovigilance data
• Tier 4 – Expert commentary: Published analysis from credentialed researchers, institutional position statements
• Tier 5 – Community reports: Forum discussions, user experience reports (cited as anecdotal only, never as evidence)

The following are never treated as credible primary sources: vendor marketing materials, product descriptions, social media testimonials, influencer endorsements, or promotional content of any kind.

Before publication, all factual claims in an article are cross-referenced against their source material. Specific checks include:

• Regulatory status claims verified against current FDA, MHRA, and TGA primary source databases
• Clinical trial results confirmed against the published study data, not press releases or secondary reporting
• Statistical claims checked against the original data sets
• Legal and regulatory frameworks verified for each jurisdiction referenced

Where evidence is insufficient to support a definitive claim, the article explicitly states the limitations of available data. We do not fill gaps in the evidence base with editorial speculation.

The peptide landscape changes frequently. Regulatory decisions, new clinical data, and enforcement actions can materially alter the accuracy of previously published content. PeptideGuider.com maintains its content through the following process:

• Articles are reviewed when significant regulatory changes occur affecting the compounds covered
• New clinical data from published trials triggers a review of relevant articles
• All articles display a last-reviewed date so readers can assess the currency of the information
• Outdated articles are either updated or clearly marked as requiring review

When errors are identified in published content, they are corrected promptly. Material corrections – those that change the factual substance of an article – are accompanied by a visible correction note stating what was changed and when. Minor corrections such as typographical fixes or formatting adjustments do not require a correction note.

We take accuracy seriously. If you believe an article contains a factual error, please contact us at contact@peptideguider.com with the article URL and details of the error. We will review and respond within 48 hours.

Certain categories of content fall outside the scope of PeptideGuider.com’s editorial mission and will not be published on this site:

• Dosing protocols or injection guides
• Sourcing recommendations framed as medical or health advice
• Vendor rankings or reviews influenced by commercial relationships
• Content that presents vendor marketing claims as established fact
• Sponsored articles, paid reviews, or commercially motivated editorial content

PeptideGuider.com has no commercial relationships with any peptide vendor, supplier, or manufacturer. No vendor pays for editorial placement, influences article content, or receives preferential coverage. Editorial decisions are made solely on the basis of reader interest and informational value.

Should the site’s commercial model change in the future, any relationships that could reasonably be perceived as conflicts of interest will be disclosed transparently on this page.